Literature DB >> 19701692

Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.

Hui Zhao1, Wei Guo, Changliang Peng, Tao Ji, Xinchang Lu.   

Abstract

Given that arsenic trioxide (As(2)O(3)) has been successfully used as a chemotherapeutic agent for refractory malignant tumors, this study is aimed at investigating the effect of As(2)O(3) on human Adriamycin resistant osteosarcoma cell line Saos-2. The mechanism underlying multi drug resistance (MDR) in osteosarcoma cells and the anti-tumor effect of As(2)O(3) on Adriamycin resistant osteosarcoma cells were analyzed. In our experiment, we first selected Adriamycin resistant osteosarcoma cell line by growing the classic osteosarcoma cell line Saos-2 in the medium with increasing drug concentrations. Then, we compared the IC50s of the osteosarcoma cells treated with different anticancer drugs by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Subsequently, we assessed the expression of classic MDR related molecules, Pgp, multidrug resistance-associated protein (MRP) and glutathione (GSH) activity in the wild type and Adriamycin resistant Saos-2 cells. Furthermore, the apoptosis was assessed by concerning DNA fragment and flow cytometry with Annexin-V staining. To elucidate the underlying mechanism of the apoptosis, related proteins Bcl-2, Bcl-xL, Bax, Bak, cleaved Caspase-3 and cleaved Caspase-9 were analyzed by western blotting. The data showed that the resistance to Adriamycin affected the sensitivity of osteosarcoma cell to other chemotherapeutic agents. The IC50s of Saos-2/ADM cells for methotrexate (1.74-fold), Cisplatin (1.43-fold) and As(2)O(3) (1.21-fold) were increased compared with Saos-2 control cells. The expression of Pgp was upregulated comparing with the control cells. No significant difference was detected about the MRP and the glutathione-S-transferase activity and intracellular GSH concentration among different treated osteosarcoma cells. Apoptosis was observed and proved. The western blotting showed that the expression of Bcl-2 and Bcl-xL was downregulated. Meanwhile, the level of Bax, Bak, cleaved Caspase-3 and cleaved Caspase-9 was upregulated after treated with As(2)O(3). The study suggests that Adriamycin resistant osteosarcoma cells have good response to As(2)O(3)-based chemotherapy in vitro, probably via the pathway of inducing apoptosis. And As(2)O(3) might serve as an excellent alternative candidate for adjuvant chemotherapeutic agent on this incurable pediatric sarcoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701692     DOI: 10.1007/s11033-009-9765-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  31 in total

1.  Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression.

Authors:  B van Triest; H M Pinedo; F Telleman; C L van der Wilt; G Jansen; G J Peters
Journal:  Biochem Pharmacol       Date:  1997-06-15       Impact factor: 5.858

2.  Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.

Authors:  Stephan Mathas; Andreas Lietz; Martin Janz; Michael Hinz; Franziska Jundt; Claus Scheidereit; Kurt Bommert; Bernd Dorken
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

Review 3.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

4.  Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.

Authors:  G Saeter; T A Alvegård; I Elomaa; A E Stenwig; T Holmström; O P Solheim
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

5.  Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.

Authors:  Guillermo Lazo; Hagop Kantarjian; Elihu Estey; Deborah Thomas; Susan O'Brien; Jorge Cortes
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

6.  Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.

Authors:  P Bader; J Fuchs; M Wenderoth; D von Schweinitz; D Niethammer; J F Beck
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

7.  Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.

Authors:  Qun Liu; Susan Hilsenbeck; Yair Gazitt
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

8.  Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel.

Authors:  Kohji Takara; Yukihisa Obata; Eri Yoshikawa; Noriaki Kitada; Toshiyuki Sakaeda; Noriaki Ohnishi; Teruyoshi Yokoyama
Journal:  Cancer Chemother Pharmacol       Date:  2006-03-14       Impact factor: 3.333

9.  Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

Authors:  H Diddens; D Niethammer; R C Jackson
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

10.  JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.

Authors:  Kelly Davison; Koren K Mann; Samuel Waxman; Wilson H Miller
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

View more
  10 in total

1.  PpGalNacT2 participating in vanadium-induced HL-60 cell differentiation.

Authors:  Yuan Gao; You Bin Tu; Yi Guo; Ling Yan Yang; Xiang Hong Guo; Lan Xu; Zheng Rong Xu; Shi Liang Wu
Journal:  Mol Biol Rep       Date:  2010-09-29       Impact factor: 2.316

2.  Adenovirus-delivered PDCD5 counteracts adriamycin resistance of osteosarcoma cells through enhancing apoptosis and inhibiting Pgp.

Authors:  Hui Zhao; Changliang Peng; Guorui Ruan; Junlin Zhou; Yihan Li; Yong Hai
Journal:  Int J Clin Exp Med       Date:  2014-12-15

3.  Andrographolide inhibits proliferation of human lung cancer cells and the related mechanisms.

Authors:  Xiangyu Luo; Weimin Luo; Chenyi Lin; Li Zhang; Yaling Li
Journal:  Int J Clin Exp Med       Date:  2014-11-15

4.  DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells.

Authors:  Minhua Feng; Bo Huang; Zunguo Du; Xiaoping Xu; Zi Chen
Journal:  Mol Biol Rep       Date:  2010-10-01       Impact factor: 2.316

5.  Characteristics of doxorubicin-selected multidrug-resistant human leukemia HL-60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells.

Authors:  Jing Chen; Hulai Wei; Jie Cheng; Bei Xie; Bei Wang; Juan Yi; Baoying Tian; Zhuan Liu; Feifei Wang; Zhewen Zhang
Journal:  Oncol Lett       Date:  2017-11-06       Impact factor: 2.967

6.  Targeted therapies for bone sarcomas.

Authors:  Dominique Heymann; Françoise Rédini
Journal:  Bonekey Rep       Date:  2013-07-17

7.  Effects of Arsenic Trioxide on Minor Progressive High-Grade Osteosarcoma of the Extremities Metastatic to the Lung: Results of 39 Patients Treated in a Single Institution.

Authors:  Lu Xie; Wei Guo; Xiaodong Tang; Yi Yang; Jie Xu
Journal:  Case Rep Oncol       Date:  2016-10-17

8.  A Novel Resveratrol-Arsenic Trioxide Combination Treatment Synergistically Induces Apoptosis of Adriamycin-Selected Drug-Resistant Leukemia K562 Cells.

Authors:  Jing Chen; Baoying Tian; Cunmin Zhou; Jingjing Sun; Li Lin; Shucheng Jin; Quanrui Liu; Siyu Fu; Lian Liu; Hang Liu; Zhewen Zhang; Caili Li; Hulai Wei
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

9.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27

10.  Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.

Authors:  Hai-Ying Hua; Hua-Qiang Gao; Ai-Ning Sun; Jian-Nong Cen; Li-Li Wu
Journal:  Mol Med Rep       Date:  2016-09-26       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.